Topical Tacrolimus for Psoriasis

Abstract

Tacrolimus ointment is an agent approved for the treatment of atopic dermatitis; however, tacrolimus has been expected also as one of the promising therapeutic strategies for other T-cell mediated inflammatory skin disorders. Recent progress have demonstrated that topical tacrolimus shows beneficial effects for psoriasis depending on sites. In particular, facial, intertriginous, and genital psoriasis respond to topical tacrolimus dramatically in a short period. Further, topical tacrolimus is tolerable also for child psoriasis. Because topical tacrolimus does not induce either skin atrophy or telangiectasia different from corticosteroids, it is recommended to be a first choice. The most proper way of topical tacrolimus therapy at present is to use this ointment intermittently after the remission was once obtained, paying attention to its adverse effects.

Implementation of Design of Experiments in Development and Optimization of Transfersomal Carrier system of Tacrolimus for the Dermal Management of Psoriasis in Albino Wistar Rat

“…Psoriasis is a chronic inflammatory skin disorder typically characterized by erythematous plaques covered with silver or white scale on the surface and histologically characterized by proliferation of epidermis with parakeratosis, polymorphonuclear leukocyte infiltration in the stratum coreum, dilation of superficial blood vessels [1]. Whereas atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by an itchy, erythmatous and intensely pruritic rash with periods of exacerbation and remission [2].…”